Egetis to host Investor Day on December 19, 2023

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment

Emcitate®

Our lead product candidate

Pipeline

General Corporate presentation

Press Releases

December 1, 2023

Save the Date: Egetis to host Investor Day on December 19, 2023

Read more

Regulatory

November 10, 2023

Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan

Read more

Regulatory

November 8, 2023

Interim report Q3 2023

Read more

Upcoming event

December 19, 2023

Egetis Investor Day

Latest presentation

November 8, 2023

Interview with Nicklas Westerholm, CEO, by Redeye

Latest Report

November 8, 2023

Q3 Report 2023

Calendar and upcoming reports

December 14, 2023

DNB Nordic Healthcare Conference

December 19, 2023

Egetis Investor Day

February 22, 2024

Year-end Report Q4 2023

May 3, 2024

Interim Report Q1 2024

May 6, 2024

Annual General Meeting

Joshua’s Story

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com

Cookies
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept all”, you consent to the use of ALL the cookies. However, you may visit "Settings" to provide a controlled consent. Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
Save Accept all